JPRN-jRCT2031220244招募中未知
Specified drug use Surveillance for ADCETRIS Intravenous Infusion 50 mg -Untreated CD30 positive Hodgkin lymphoma (Pediatric)
Contact for Clinical Trial Information0 个研究点目标入组 8 人开始时间: 2022年8月5日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 < 18age old（—）
- 性别
- All
入选标准
- •1.Treatment-naive participants
- •2.CD30 positive participants
- •3.Participants treated with the study drug in combination with doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine (AVD).
- •4.Participants aged < 18 years at the start of this drug.
排除标准
- •Participants with contraindications to the study drug.
研究者
相似试验
已完成
不适用
Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion Untreated CD30-Positive Hodgkin's LymphomaJPRN-jRCT1080224121Takeda Pharmaceutical Company Limited113
已完成
不适用
Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion Relapsed or refractory CD30-positive peripheral T cell lymphoma or Pediatric Hodgkin LymphomaPeripheral T cell lymphoma and Pediatric Hodgkin lymphomaJPRN-jRCT1080224999Takeda Pharmaceutical Company Limited95
未知
Unknown
ADCETRIS IV Infusion - Special drug use surveillance (all-case surveillance) Relapsed or refractory CD30+ Hodgkin's lymphoma or anaplastic large cell lymphomaRelapsed or refractory CD30+ Hodgkin's lymphoma or anaplastic large cell lymphomaJPRN-jRCT1080222405TAKEDA PHARMACEUTICAL COMPANY LTD.140
已完成
不适用
Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Untreated CD30-Positive Hodgkin's Lymphoma"Untreated CD30-Positive Hodgkin's LymphomaNCT03729609Takeda113
已完成
不适用
TECENTRIQ Drug Use Surveillance(advanced or recurrent non-small cell lung cancer)non-small cell lung cancerJPRN-UMIN000031978Chugai Pharmaceutical Co. Ltd.1,000